Document:

Employment offer letter to Phillip Rose

 Exhibit 10.1 
 May 22, 2008 
 Phillip Rose 
 [Address]

 Dear Phil, 
 Per our discussions, we would like to take this
opportunity to offer you the position of Chief Operating Officer with our organization. The table below outlines the terms of your employment at Senetek PLC. 
  

			
	Title	 	Chief Operating Officer
		
	Employment Start Date	 	To be discussed with and agreed upon by Frank Massino
		
	Annual Salary	 	$240,000
		
	Equity	 	40,000 Stock Options (at market price on the date of grant)
		
	Report To	 	Frank J. Massino, Chairman & CEO
		
	Location	 	Napa Headquarters or Southern California, subject to discussion and approval with Frank Massino
		
	Bonus Plan	 	Eligible for pro rata participation in Management Bonus Program

			
		
	401K	 	Eligible for enrollment in Company’s 401K plan in accordance with its terms
		
	Employee Benefits	 	Eligible for enrollment in Company’s medical, dental, group life and disability insurance plans effective immediately

 We look forward to having you as a member of our team. 
 Sincerely, 
 Corena Michnevich 
 Vice President, Human Resources 
 Senetek PLC 
  

					
	AGREED TO AND ACCEPTED BY:	 		 	
			
	  	 		 	  
	Phillip Rose	 		 	Date

 Additional Agreed Upon Terms on May 27, 2008: 
  

	 	1.	Senetek to underwrite relocation of automobile and personal items to California (to be kept under $2000). 

  

	 	2.	Senetek to underwrite up to 3 month temporary housing in Napa. 

  

	 	3.	Senetek to provide necessary equipment such as Blackberry or laptop computer. 

  

	 	4.	Senetek to include a 2 month severance package – in the event employee is terminated for anything other than cause.Press release

 Exhibit 10.2 
 Press Release 
 Source: Senetek PLC 
 Senetek PLC Announces Key Personnel Appointments 
 Phillip Rose Named Chief Operating Officer 
 NAPA, Calif., June 9, 2008/PRNewswire-First Call/ — Senetek
PLC (OTCBB: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that the Company has appointed Veteran Sales and Marketing Executive, Phillip Rose, as its Chief
Operating Officer and retained J. David Bruner as a full-time marketing consultant. 
 Phillip Rose has thirty years of experience in domestic and
international sales, marketing, commercial development, licensing, regulatory affairs and general executive management of large public and multi-national pharmaceutical research, development and sales and marketing organizations. For nine years,
Mr. Rose was Vice President of Corporate Sales for Glaxo Pharmaceuticals, Inc. In 1997 he became Vice President and General Manager of North American Operations for ICN Pharmaceuticals, Inc. (now Valeant Pharmaceuticals). He then went on to
become President and CEO of Obagi Medical Products, a specialty pharmaceutical company focused in aesthetic medicine, selling products and services directly through dermatologists and plastic surgeons, as well as a network of wholly owned
subsidiaries and distributors, internationally. He is a graduate of Union University, Albany College of Pharmacy, and is a licensed pharmacist. 
 David
Bruner has over 20 years experience in specialty pharmaceuticals and has held executive level marketing positions at Neutrogena, Obagi Medical Products, Inc., ICN Pharmaceuticals, Inc. (now Valeant Pharmaceuticals) and Stiefel Laboratories.
Mr. Bruner holds an MBA from Pepperdine University and an undergraduate degree from the University of Minnesota. 
 Mr. Rose and Mr. Bruner worked together at ICN Pharmaceuticals, Inc. successfully launching Kinerase®, the leading antiaging brand in the physician
market in North America. They continued their successes at Obagi Medical Products and were responsible for the acquisition and development of the Obagi highly successful Vitamin C product line. 
 Phillip Rose commented on the clinical data supporting Pyratine-6TM, stating “that Pyratine-6TM has demonstrated a high degree of clinical efficacy in
treating subjects with photodamaged skin and proved most beneficial in patients with acne rosacea. He went on to note that Pyratine-6TM worked faster than Kinerase and in a comparative analysis completed by the investigators of both Kinerase and
Pyratine-6TM, Pyratine-6TM showed superiority in the reduction of fine lines and wrinkles, improving skin texture and reducing mottled hyperpigmentation”. 

 Mr. Bruner stated he was, “most pleased to be associated with Senetek and have the opportunity to help launch a
superior product such as Pyratine-6TM, working along side Phil Rose. Pyratine-6TM has multiple differential advantages over the competition, not to mention its positive effects on skin cells, its antioxidant properties and its ability to
increase the moisture content in skin, which is essential for healthy skin.” 
 “Phillip and David are great additions to the Senetek team, having
had great successes in the physician market, launching new products. They bring with them a thorough understanding of the market along with key relationships with influential physicians and thought leaders”, commented Frank Massino,
Chairman & Chief Executive Officer of Senetek. 
 * * * * * * * 
 About Senetek PLC 
 Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough
technologies that target the science of healthy aging. The Company’s extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in
dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in
the North American physician market. 
 For more information, visit the company’s website at http://www.senetekplc.com. 
 This news release contains statements that may be considered ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform
Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could
result in such material differences are described in the Company’s Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result
in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information,
future events or otherwise. 
 Company contact: 
 Senetek, PLC 
 1-707-226-3900 ext. 102THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE
NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT
BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE
REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION
FROM REGISTRATION. THE COMPANY MAY REFUSE TO AUTHORIZE ANY TRANSFER OF THE
SECURITIES IN RELIANCE ON AN EXEMPTION FROM REGISTRATION UNTIL IT HAS RECEIVED
AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH
REGISTRATION IS NOT REQUIRED.

THE COMPANY IS AUTHORIZED TO ISSUE MORE THAN ONE CLASS OF STOCK OR MORE THAN ONE
SERIES OF ANY CLASS OF STOCK. THE DESIGNATIONS, PREFERENCES AND RELATIVE,
PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF THE SHARES OF EACH CLASS OR
SERIES THEREOF AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH
RIGHTS, ARE SET FORTH IN THE ARTICLES OF INCORPORATION OF THE COMPANY. A COPY OF
SAID ARTICLES OF INCORPORATION WILL BE FURNISHED FREE OF CHARGE TO THE HOLDER OF
THIS CERTIFICATE UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.

THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF MAY BE
TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE
COMPANY AND THE HOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE
COMPANY.

                      BIOFORCE NANOSCIENCES HOLDINGS, INC.

                       CONVERTIBLE SECURED PROMISSORY NOTE

Principal Amount:  $__________                                     June 10, 2008

BioForce Nanosciences Holdings, Inc. (the "Company") for value received,
promises to pay to the order of _____________________ (the "Purchaser"), the
principal amount set forth above plus interest thereon calculated from the date
hereof until paid in full at eight percent (8%) per annum compounded annually.
In the Event of Default (as defined below) interest shall be calculated at
fifteen percent (15%) per annum, compounded annually, until the Note is paid in
full. Except in the Event of Default, principal and interest accrued hereunder
but unpaid will be due and payable in lawful money of the United States in full
on June 10, 2009 (the "Maturity Date"), unless (i) this Note has been previously
converted pursuant to Section 2 hereof, in which case all outstanding principal
and accrued interest under this Note shall be satisfied in full by virtue of
such conversion and the issuance and delivery of fully paid and non-assessable
debt or equity securities to the Purchaser as set forth in Section 2 hereof,
(ii) this Note has been previously redeemed pursuant to Section 4 or Section 5
hereof, in which case all accrued interest shall be paid on the redemption date.

<PAGE>

      The following is a statement of the rights of the Purchaser and the
conditions to which this Note is subject, and to which the Purchaser, by the
acceptance of this Note, agrees:

      1. Definitions. As used in this Note, the following terms, unless the
context otherwise requires, have the following meanings:

            1.1. "Common Stock" shall mean the Common Stock, $0.001 par value
per share, of the Issuer and any other Capital Stock into which such stock may
hereafter be changed.

            1.2. "Conversion Price" means the Warrant Price as defined in
Warrant to Purchase Shares of Common Stock (the "Warrant") issued to the
Purchaser by the Company on the date of this note, and pursuant to the
Convertible Secured Promissory Note and Warrant Purchase Agreement between the
Company, the Purchaser, and other parties as of the same date. If the Warrant is
no longer outstanding as of the date of conversion of this Note, the Conversion
Price shall be the Warrant Price that would have been in effect on the date of
conversion of the Note had the Warrant still been outstanding.

            1.3. "Financing" shall mean the Company's sale or issuance, from and
after the date hereof, of its equity securities, or debt securities convertible
into Common Stock, for cash (excluding securities issued upon the exercise of
options or upon the exercise of warrants or other convertiible debt securities
of the Company outstanding on the date hereof or upon the conversion of the
Notes) in one transaction or a series of transactions occurring after the date
hereof, which results in the receipt by the Company of at least $1,000,000 in
proceeds from one or more investors.

            1.4. "Financing Price" shall mean the price per share or other unit
at which the Company sells its equity securities, or debt securities convertible
into Common Stock, in the first Financing following the date hereof.

            1.5. "Financing Securities" shall mean the class or series of equity
or debt securities that the Company issues or sells in connection with the first
Financing following the date hereof.

            1.6. "Note" shall mean this convertible secured promissory note.

            1.7. "Person" shall mean any individual, corporation, partnership,
joint venture, trust, business association, organization, governmental authority
or other entity.

      2. Conversion.

            2.1. Voluntary Conversion by the Purchaser. At any time prior to
this Note being paid in full, the Purchaser shall have the right, but not the
obligation, to convert all but not less than all of the principal and interest
due under this Note into shares of the Company's Common Stock at the Conversion

                                      -2-
<PAGE>

Price. Upon a voluntary conversion pursuant to this Section 2.1, the Purchaser
shall provide the Company written notice of its intent to convert. The Company
shall then issue the Common Stock upon surrender of this Note for conversion at
the principal office of the Company.

            2.2. Voluntary Conversion Associated with Subsequent Financing. At
any time prior to this Note being paid in full, if the Company consummates an
equity financing, or a debt financing where that debt is convertible into equity
securities, the Purchaser may exchange the Note for the securities issued in
such financing on the terms of the subsequent offering. The Company shall
provide the Purchaser of notice of any debt or equity offerings while this Note
is outstanding. If the Purchaser wishes to convert this Note under Section 2.2,
the Purchaser shall provide the Company with written notice of its intent to
convert within fifteen days of receipt of notice from the Company of a
subsequent financing. The Company shall then issue the applicable debt or equity
securities upon surrender of this Note for conversion at the principal office of
the Company.

            2.3. Mandatory Conversion. This Note shall automatically convert
simultaneous with the closing of a Financing. Upon a mandatory conversion
pursuant to this Section 2.3, the Company shall provide the Purchaser notice
thereof and the Purchaser shall surrender of this Note for conversion at the
principal office of the Company. The Purchaser shall have the option of
converting this note into i) Financing Securities at the Financing Price, or ii)
shares of the Company's Common Stock at the then applicable Conversion Price,
and will provide the Company with written notice of which conversion option it
chooses within five business days of receipt of notice from the Company that a
Financing has occurred.

            2.4. No Fractional Shares. No fractional shares will be issued on
conversion of this Note. If on any conversion of this Note a fraction of a share
results, the Company will pay the cash value of that fractional share,
calculated on the basis of the applicable Conversion Price.

            2.5. Fully Paid Shares. All shares of Common Stock or Financing
Securities issued or transferred upon the conversion of this Note shall be
validly issued, fully paid, non-assessable and free and clear of any claims,
liens or encumbrances.

            2.6. Certain Representations. The Company hereby represents and
warrants that it has taken all necessary corporate action and obtained all
necessary consents and approvals to authorize the issuance of this Note.

            2.7. No Rights as Stockholder. Except in the event of conversion,
this Note does not by itself entitle the Purchaser to any voting rights or other
rights as a stockholder of the Company. In the absence of conversion of this
Note, no provisions of this Note, and no enumeration herein of the rights or
privileges of the Purchaser shall cause such Purchaser to be a stockholder of
the Company or for any purpose by virtue hereof.

      3. Securities Law Matters. The Purchaser is an "accredited investor"
within the meaning of Rule 501(a) of Regulation D under the Securities Act of
1933, as amended (the "Securities Act") and has such knowledge or experience in
financial and business matters to enable the Purchaser to evaluate the merits

                                      -3-
<PAGE>

and risks of acquiring the Note. The Purchaser has had the opportunity to
discuss with the Company's management, the Company's business and financial
affairs. The Purchaser is acquiring this Note for the Purchaser's own account
for investment and with no intention of distributing or reselling such Note or
any part thereof in any transaction which would constitute a "distribution"
within the meaning of the Securities Act. The Purchaser acknowledges that (i)
this Note and the Conversion Securities have not been registered under the
Securities Act or any state securities law, (ii) the Purchaser must continue to
bear the economic risk of the investment in this Note and the Conversion
Securities unless such securities are subsequently registered under the
Securities Act and applicable state securities law or such registration is not
required, and (iii) there is not now, and in the future there may not be, any
public market for this Note or the Conversion Securities. The Purchaser
understands and acknowledges that this Note and the Conversion Securities shall
have a restrictive legend to reflect the facts set forth in subsections (i) and
(ii). The Purchaser understands that this Note is a speculative investment which
involves a high degree of risk of loss of its investment therein and that it may
not be possible to liquidate such investment in the Company in case of
emergency, if at all. The Purchaser has had the opportunity to ask all questions
and receive all answers concerning the Company and the terms and conditions of
the purchase of this Note which the Purchaser deems necessary in order to make
an informed decision to purchase this Notes.

      4. Redemption. The Company can redeem all of the outstanding Notes at any
time, other than upon a change of control as described below, upon thirty (30)
days notice at a redemption price equal to 120% of the then outstanding
principal amount plus accrued interest and other charges. Holders of the Notes
called for redemption may exercise their right to convert any or all of their
Notes pursuant to Section 2 at any time prior to the close of business on the
date set for redemption.

      5. Liquidation. In the event of a liquidation, dissolution or winding up
of the Company prior to the Maturity Date, the Purchaser will have the right to
receive immediately an amount equal to the 120% of the outstanding principal
amount plus accrued, unpaid interest of this Note held by the Purchaser. Holders
of the Notes may exercise their right to convert any or all of their Notes
pursuant to Section 2 at any time prior to the close of business on the date set
for liquidation.

      6. Collateral. As security for this Note, Company hereby grants to
Purchaser a security interest in all of its assets, including assets of its
subsidiary, BioForce Nanosciences, Inc., including but not limited to accounts
receivable, inventory, property and equipment, and intangible assets including
intellectual property. A UCC-1 Financing Statement in a form acceptable to the
Purchaser, and any other documents reasonably requested by Purchaser to perfect
their security interest, appropriately completed by and duly executed by the
Company, shall be filed with the appropriate governmental agency.

      7. Registration Rights. If at any time when there is not an effective
Registration Statement covering the shares of Common Stock issuable upon the
conversion of this Note (the "Conversion Shares"), the Company shall determine
to prepare and file with the Commission a registration statement relating to an
offering for its own account or the account of others under the Securities Act
of any of its equity securities, other than on Form S-4 or Form S-8 (each as

                                      -4-
<PAGE>

promulgated under the Securities Act) or their then equivalents relating to
equity securities to be issued solely in connection with any acquisition of any
entity or business or equity securities issuable in connection with stock option
or other employee benefit plans, the Company shall send to each Holder written
notice of such determination and, if within thirty (30) days after receipt of
such notice, or within such shorter period of time as may be specified by the
Company in such written notice as may be necessary for the Company to comply
with its obligations with respect to the timing of the filing of such
registration statement, any such Holder shall so request in writing, (which
request shall specify the Conversion Shares intended to be disposed of by the
Purchasers), the Company will cause the registration under the Securities Act of
all Conversion Shares which the Company has been so requested to register by the
Holder, to the extent requisite to permit the disposition of the Conversion
Shares so to be registered, provided that if at any time after giving written
notice of its intention to register any securities and prior to the effective
date of the registration statement filed in connection with such registration,
the Company shall determine for any reason not to register or to delay
registration of such securities, the Company may, at its election, give written
notice of such determination to such Holder and, thereupon, (i) in the case of a
determination not to register, shall be relieved of its obligation to register
any Conversion Shares in connection with such registration, and (ii) in the case
of a determination to delay registering, shall be permitted to delay registering
any Conversion Shares being registered pursuant to this Section 7 for the same
period as the delay in registering such other securities. The Company shall
include in such registration statement all or any part of such Conversion Shares
such Holder requests to be registered; provided, however, that the Company shall
not be required to register any Conversion Shares pursuant to this Section 7
that are eligible for sale pursuant to Rule 144(k) of the Securities Act. In the
case of an underwritten public offering, if the managing underwriter(s) or
underwriter(s) should reasonably object to the inclusion of the Conversion
Shares in such registration statement, then if the Company after consultation
with the managing underwriter should reasonably determine that the inclusion of
such Conversion Shares would materially adversely affect the offering
contemplated in such registration statement, and based on such determination
recommends inclusion in such registration statement of fewer or none of the
Conversion Shares of the Holders, then (x) the number of Conversion Shares of
the Holders included in such registration statement shall be reduced pro-rata
among such Holders (based upon the number of Conversion Shares requested to be
included in the registration), if the Company after consultation with the
underwriter(s) recommends the inclusion of fewer Conversion Shares, or (y) none
of the Conversion Shares of the Holders shall be included in such registration
statement, if the Company after consultation with the underwriter(s) recommends
the inclusion of none of such Conversion Shares; provided, however, that if
securities are being offered for the account of other persons or entities as
well as the Company, such reduction shall not represent a greater fraction of
the number of Conversion Shares intended to be offered by the Holders than the
fraction of similar reductions imposed on such other persons or entities (other
than the Company). Nothing in this section shall limit the registration rights
that the Purchase may have under any other agreement.

      8. Events of Default; Remedies. The term "Event of Default" shall mean the
occurrence of any one or more of the following:

                                      -5-
<PAGE>

            8.1. The failure of the Company to pay any amounts due hereunder
when due and such failure continues for a period of fourteen (14) days after
written notice thereof by the Purchaser;

            8.2. A material breach by the Company of any other term or provision
of this Note, or the Convertible Secured Promissory Note and Warrant Purchase
Agreement dated June 10, 2008, that remains uncured twenty one (21) days after
the Company becomes aware of such breach;

            8.3. The Company shall have entered against it by a court having
jurisdiction thereof a decree or order for relief in respect to the Company
under any applicable bankruptcy, insolvency or other similar law now or
hereafter in effect, or a receiver, liquidator, assignee, custodian, trustee,
sequestrator or other similar official shall be appointed for the Company or for
any substantial part of the Company's property, or the winding up or liquidation
of the Company's affairs shall have been ordered; or the Company shall commence
a voluntary case under any applicable bankruptcy, insolvency or other similar
law now or hereafter in effect, or consent to the entry of an order for such
relief in an involuntary case under any such law, or any such involuntary case
shall commence, and not be dismissed within sixty (60) days, or the Company
shall consent to the appointment of or taking possession by a receiver,
liquidator, assignee, trustee, custodian, sequestrator or other similar official
for the Company or for any substantial part of the Company's property, or make
any general assignment for the benefit of creditors; or

Upon the occurrence and continuance of an Event of Default, the Purchaser is
entitled to declare all or any portion of the outstanding principal amount of
the Note (together with all accrued but unpaid interest thereon and all other
amounts due in connection therewith) due and payable and demand immediate
payment thereof.

      9. Convertible Secured Promissory Note and Warrant Purchase Agreement.
Except as otherwise expressly provided herein, this Note shall be subject to the
terms and conditions of the Convertible Secured Promissory Note and Warrant
Purchase Agreement, by and among the Company and the Purchaser and dated as of
June 10, 2008.

                    [signatures appear on the following page]

                                      -6-
<PAGE>

      IN WITNESS WHEREOF, each party has caused this Note to be signed in its
name on the date first written above.

Company:

BIOFORCE NANOSCIENCES HOLDINGS, INC.

By:  _______________________________

Name:_______________________________

Title:______________________________

Purchaser:

____________________________________

By:_________________________________

Name:_______________________________

Title:______________________________

                                      -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]